[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Universidad de Antioquia\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":249},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,45,75,102,128,160,185,213],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100579298","phase-3-arnica-tincture-fot-the-treatment-of-cutaneous-leishmaniasis-ii-100579298",false,"NCT06822478","Arnica Tincture Fot the Treatment of Cutaneous Leishmaniasis II.","Randomized Blinded Clinical Trial to Evaluate the Safety and Efficacy of Arnica Tincture in the Topical Treatment of Cutaneous Leishmaniasis.","ARNICA","Inclusion Criteria:\n\nParticipants who meet the following inclusion criteria may enter the study and receive arnica tincture or intralesional pentavalent antimonials:\n\n1\\. Males or females, over 12 years of age and adults without age limit. With a confirmed parasitological diagnosis of a primary infection of LC in at least one lesion, made by one of the following methods: 1) microscopic identification of amastigotes in the lesion tissue; 2) diagnosis of leishmania by PCR; 3) positive culture for promastigotes (Annex 2).\n\n3\\. With clinical diagnosis of localized LC. 4. Ulcer, nodule or plaque type lesions. Up to 9 lesions in total, and that the total area of all lesions is ≤1875 mm2 6. Subjects who have given written IC\u002FAssent. 7. Subject is able to understand and comply with the requirements of the study. 8. Subjects who are able to attend the control visits.\n\nExclusion Criteria:\n\nParticipants presenting one or more of the following criteria should be excluded from the study:\n\n1. Diagnosis or suspicion of mucosal\u002Fmucocutaneous, diffuse or disseminated Leishmaniasis or relapse or reactivation of an LC.\n2. Subjects with lesions involving the auricular region, orbital region, nasal region and\u002For labial region of the face, joints or in places that, in the opinion of the investigator, are difficult to apply topically or intralesionally to the study medication.\n3. History of clinically significant cardiovascular, renal, hepatic, hepatic, neurological or immunological diseases that may interact positively or negatively with the treatment.\n4. Having received treatment for Leishmaniasis or other treatment that, in the judgment of the investigator, may modify the course of infection with Leishmania in the last 8 weeks (56 days) prior to admission.\n5. Women with a positive pregnancy test during the screening process, or lactating, or women of childbearing age who do not agree to the use of contraceptives during treatment and until DPT45.\n6. Known or suspected history of hypersensitivity or idiosyncratic reactions to the investigational product or pentavalent antimonials in the trial.\n7. Subjects who are unwilling to attend study visits or who are unable to comply with follow-up visits for up to three months.","ALL","12 Years",{"count":20,"type":21},96,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","Cutaneous leishmaniasis (CL) is a parasitic disease caused by more than 20 different species of the protozoan parasite Leishmania. CL usually begins with a papule at the site of the sandfly bite, which enlarges to form a nodule that progresses to an ulceration, or a scaly or warty plaque, over a period of 1 to 3 months.\n\nThe exact incidence of CL is not known. An estimated 1.2 million cases\u002Fyear in approximately 100 countries worldwide suffer from different forms of CL. More than 90% of CL cases occur in the Americas and Eastern Mediterranean regions. Afghanistan, Algeria, Brazil, Colombia, Iraq, Pakistan, and Syria report more than 80% of new CL cases worldwide. Since 2010, the World Health Organization has insisted on the need to work on products that become alternatives for the treatment of LC, especially in products that can be applied topically because with them the probability of systemic toxicity is lower, increasing patient safety.\n\nCurrently, it is recommended to apply local treatments for patients with localized LC, either with pentavalent antimonials administered intralesionally or with thermotherapy. Among the options for topical treatment are natural products that have been, are and will be of utmost importance as sources of medicinal agents. In addition to natural products that have found direct medicinal applications as pharmaceutical entities, many others can serve as chemical models or templates for the design, synthesis and semi-synthesis of novel substances for the treatment of human diseases.\n\nArnica montana L. is a plant with anti-emollient, healing, anti-inflammatory, analgesic and antineuralgic properties; it is included in the Colombian vademecum of medicinal plants.\n\nIn a randomized phase Ib\u002FII clinical trial conducted in patients with localized LC in Colombia, 100% (per protocol analysis) and 92% (intention-to-treat analysis) efficacy was demonstrated, with no adverse effects other than those expected such as erythema, burning, pain or itching.\n\nBy demonstrating that arnica tincture is effective and safe, and that A. montana flower extracts in different preparations (topical solutions, tinctures, liniments, ointments or gels) are approved by the European Medicines Agency and are included in the vademecum of Colombian plants issued by the Ministry of Social Protection of Colombia in 2008, the present study aims to establish the safety and efficacy of arnica tincture as an alternative for the topical treatment of localized LC compared to a currently available local therapeutic alternative: intralesional pentavalent antimonials.",[27],"Leishmaniasis, Cutaneous",[29,30,31],"Leishmaniasis","Cutáneo","Tintura de árnica","RECRUITING","2026-03-27",{"date":35,"type":36},"2026-04-02","ACTUAL",{"date":38,"type":36},"2026-03-11",{"date":40,"type":21},"2030-02",{"name":42,"class":43},"Universidad de Antioquia","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":56,"briefSummary":58,"conditions":59,"keywords":61,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":4},"100625844","effectiveness-and-safety-of-benemix-in-constipation-100625844","NCT07427914","Effectiveness and Safety of Benemix® in Constipation","Evaluation of the Effectiveness and Safety of Benemix®, a Functional Food, in the Management of Constipation in Adults","(Benemix-UdeA)","Inclusion Criteria:\n\n* Adults (≥18 years old) who use Benemix® for the management of constipation.\n* Participants who are using the product for the first time.\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding women.\n* Individuals with a diagnosis of severe gastrointestinal diseases, mental disorders, hemophilia, and\u002For cancer.\n* Individuals who have used laxatives within the last 7 days.","18 Years",{"count":55,"type":21},80,[57],"NA","The goal of this clinical trial is to find out whether the functional food Benemix® helps treat constipation in adults and whether it is safe to use.\n\nThe main questions this study aims to answer are:\n\nDoes Benemix® help improve bowel movement frequency and consistency in adults with constipation?\n\nWhat medical problems, if any, do participants experience while taking Benemix®?\n\nAdults with constipation will take Benemix® every day for 15 days. During the second week, participants will have either an in-person clinic visit or a telemedicine appointment for checkups and tests.\n\nParticipants will also receive follow-up phone calls to record:\n\n* daily treatment adherence\n* signs and symptoms\n* the number of bowel movements each day.",[60],"Constipation - Functional",[60,62,63,64,65],"Funtional food","Turmeric","Onion","Magnesium","NOT_YET_RECRUITING","2026-02-16",{"date":69,"type":36},"2026-02-23",{"date":71,"type":21},"2026-07",{"date":73,"type":21},"2026-12",{"name":42,"class":43},{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":81,"eligibilityCriteria":82,"healthyVolunteers":83,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":84,"targetDuration":4,"studyType":22,"phases":86,"briefSummary":87,"conditions":88,"keywords":94,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":99,"leadSponsor":101,"locationsCount":4},"100614475","yoga-meditation-and-mindful-eating-intervention-in-university-students-100614475","NCT07280078","Yoga, Meditation and Mindful Eating Intervention in University Students","Evaluation of a Yoga, Meditation and Mindful Eating Intervention for the Control of Stress, Anxiety, Depression, and Mindfulness in University Students","Yoga-UDEA","Inclusion Criteria:\n\n* Undergraduate students enrolled in the curso \"Yoga, Meditation, and Mindful Eating\" at the Faculty of Pharmaceutical and Food Sciences (CIFAL), University of Antioquia.\n* Willing to participate voluntarily and complete all study assessments.\n* Able to attend the full program (32 hours over one academic semester).\n\nExclusion Criteria:\n\n* Students currently practicing yoga or meditation regularly.\n* Pregnant women or participants with any medical condition that prevents safe participation in yoga practice.\n* Individuals with severe psychiatric disorders requiring pharmacological treatment.",true,{"count":85,"type":21},60,[57],"The aim of this study is to learn whether a program that combines yoga, meditation, and mindful eating can help reduce stress, anxiety, and depression, and improve mindfulness in university students.\n\nThe main questions the study aims to answer are:\n\n* Does participating in yoga, meditation, and mindful eating sessions lower students' levels of stress, anxiety, and depression?\n* Does the program improve students' mindfulness and general well-being?\n\nWhat will happen in the study:\n\nParticipants will:\n\n* Attend weekly sessions of yoga, meditation, and mindful eating for 32 hours total.\n* Practice physical postures (Asanas), breathing exercises (Pranayama), relaxation, and meditation.\n* Receive short lessons about mindful nutrition and healthy lifestyle habits.\n* Complete questionnaires before and after the program to measure stress, anxiety, depression, and mindfulness.",[89,90,91,92,93],"Stress, Psychological","Anxiety","Depression","Mindfulness","Well-being",[95],"Yoga, Meditation, Stress, Psychological; Anxiety; Well-being; Mindful Eating; Psychological",{"date":97,"type":36},"2026-02-18",{"date":71,"type":21},{"date":100,"type":21},"2026-08",{"name":42,"class":43},{"id":103,"slug":104,"hasResults":11,"nctId":105,"briefTitle":106,"officialTitle":107,"acronym":108,"eligibilityCriteria":109,"healthyVolunteers":11,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":110,"targetDuration":4,"studyType":22,"phases":112,"briefSummary":113,"conditions":114,"keywords":116,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":127},"100606736","effectiveness-of-facial-mask-niv-in-adults-under-general-anesthesia-two-hand-c-e-vs-v-e-techniques-100606736","NCT07179432","Effectiveness of Facial Mask NIV in Adults Under General Anesthesia: Two-Hand C-E vs V-E Techniques","Effectiveness of Facial Mask Non-Invasive Ventilation in Adults Under General Anesthesia: Two-Hand C-E vs V-E Techniques. A Double-Blind Randomized Trial","VENTMASK","Inclusion Criteria:\n\n* Adult patients over 18 years old\n* Scheduled for elective surgery\n* Require general anesthesia\n* Consent to participate in the study\n\nExclusion Criteria:\n\n* Presence of predictors of difficult ventilation: presence of a beard, --obstructive sleep apnea\u002Fhypopnea syndrome\n* Anticipated difficult airway\n* Classified as ASA IV or higher\n* Oxygen saturation less than 92% upon admission\n* Requirement for supplemental oxygen",{"count":111,"type":21},206,[57],"This study aims to compare two different ways doctors hold a face mask to help the participant breathe during general anesthesia. The investigators are evaluating which method, the \"C-E\" or the \"V-E\" technique, works best.\n\nIf the participant chooses to take part, on the day of surgery, after anesthesia has been administered and the participant is asleep, the doctor will use one of these two mask-holding techniques to assist breathing for a short period. The investigators will measure how effectively the participant is breathing, check carbon dioxide levels, and record the doctors' assessment of how easy and comfortable each technique was for them. This study will not alter any other aspect of the surgery or recovery.",[115],"General Anesthetics",[117,118],"ventilation","mask ventilation","2025-09-10",{"date":121,"type":36},"2025-09-17",{"date":123,"type":36},"2025-01-01",{"date":125,"type":21},"2026-08-01",{"name":42,"class":43},2,{"id":129,"slug":130,"hasResults":11,"nctId":131,"briefTitle":132,"officialTitle":133,"acronym":4,"eligibilityCriteria":134,"healthyVolunteers":11,"sex":17,"minAge":53,"maxAge":135,"enrollmentInfo":136,"targetDuration":4,"studyType":22,"phases":138,"briefSummary":139,"conditions":140,"keywords":142,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":152,"lastUpdatePostDateStruct":153,"startDateStruct":155,"completionDateStruct":157,"leadSponsor":159,"locationsCount":44},"100545146","evaluation-of-the-effect-of-consensus-based-protocols-for-the-treatment-of-minor-ailments-100545146","NCT06378099","Evaluation of the Effect of Consensus-based Protocols for the Treatment of Minor Ailments","Evaluation of the Effect of Consensus-based Protocols for the Treatment of Minor Ailments in Drugstores and Pharmacies in Medellin and the Metropolitan Area, Colombia: A Randomized Clinical Trial.","Inclusion Criteria:\n\nDrugstores and drugstores\u002Fpharmacies:\n\n* Establishments located in Medellin and Metropolitan area\n* Establishments that have a Pharmacy Technician serving as the technical director.\n* Establishments with electronic point-of-sale system for data collection.\n* Commitment to participate for the full 10-month study period.\n\nParticipants (patients):\n\n* Explicit consent to participate in the study.\n* Are the direct consumers requesting the nonprescription drug (i.e., not requesting them on behalf of someone else).\n* Present one of the five predefined potential MA that will be included in the study: influenza-like syndrome and catarrh, headache, common cold, sore throat, and menstrual pain or cramps.\n* Have access to mobile phone for follow-upThe person requesting the OTC medication must be the end consumer of it.\n\nExclusion Criteria:\n\n* Subjects who refuse to sign the informed consent\n* Subjects with an evident incapacity to complete the data questionnaire\n* Pregnant or breastfeeding women\n* Patients whose MA result from an ADR\n* Patients with symptoms lasting more than seven days","65 Years",{"count":137,"type":21},900,[57],"Minor ailments are common, self-limited conditions unrelated to the patient's underlying health problems or adverse effects of their current medications. Minor ailment services are pharmacist-led interventions that provide patients with the most appropriate recommendation when unsure about the medication for a specific minor ailment. It involves advice on nonprescription drugs, non-pharmacological measures, or referral to another health care practitioner. In Colombia, evaluating and implementing this service could optimize nonprescription drugs use and improve minor ailment management in primary health care settings.",[141],"Community Pharmacy Services",[143,144,145,146,147,148,149,150,151],"Minor ailments","Minor Ailment Services","Pharmacies","Nonprescription drugs","Pharmacy Technicians","Health education","Self care","Ambulatory care","Community Health Services","2025-08-27",{"date":154,"type":36},"2025-08-29",{"date":156,"type":36},"2024-12-04",{"date":158,"type":21},"2025-10",{"name":42,"class":43},{"id":161,"slug":162,"hasResults":11,"nctId":163,"briefTitle":164,"officialTitle":164,"acronym":4,"eligibilityCriteria":165,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":166,"targetDuration":4,"studyType":22,"phases":168,"briefSummary":169,"conditions":170,"keywords":174,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":177,"lastUpdatePostDateStruct":178,"startDateStruct":180,"completionDateStruct":182,"leadSponsor":184,"locationsCount":44},"100600066","effectiveness-of-an-educational-intervention-of-spirituality-in-nursing-professionals-working-in-critical-health-care-settings-to-promote-spiritual-self-care-100600066","NCT07092657","Effectiveness of an Educational Intervention of Spirituality in Nursing Professionals Working in Critical Health Care Settings to Promote Spiritual Self-care.","Inclusion Criteria:\n\n* Work in a critical unit of the institutions where the study will be carried out.\n* Have a minimum experience of 6 continuous months in critical care contexts.\n* Have a score of 35-45 points (moderate) and 10-30 points (low).\n\nExclusion Criteria:\n\n* Nursing professional who fails to complete full participation in the study (pre- test, nursing intervention and post-test).",{"count":167,"type":21},68,[57],"This study will evaluate the effect of an educational intervention of spirituality in nursing professionals acting in critical care contexts to favor spiritual self-care, compared with the conventional care group. The educational intervention adopts Pamela Reed's theory of the transcendence of the self as a theoretical reference, which facilitates the understanding of the phenomenon of spirituality by adopting an integral approach focused on personal growth. To determine the effect of the intervention, the Spiritual Perspective Scale (SPS) developed by Reed will be applied.",[171,172,173],"Spirituality","Nursing","Intensive Care (ICU)",[171,175,176],"Critical care nursing","Nursing care","2025-07-25",{"date":179,"type":36},"2025-07-30",{"date":181,"type":21},"2025-07",{"date":183,"type":21},"2026-02",{"name":42,"class":43},{"id":186,"slug":187,"hasResults":11,"nctId":188,"briefTitle":189,"officialTitle":190,"acronym":191,"eligibilityCriteria":192,"healthyVolunteers":11,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":193,"targetDuration":4,"studyType":22,"phases":195,"briefSummary":196,"conditions":197,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":204,"lastUpdatePostDateStruct":205,"startDateStruct":207,"completionDateStruct":209,"leadSponsor":211,"locationsCount":212},"100586158","effect-of-the-postoperative-trendelenburg-position-on-chronic-subdural-hematoma-recurrence-100586158","NCT06911736","Effect of the Postoperative Trendelenburg Position on Chronic Subdural Hematoma Recurrence","Effect of the Postoperative Trendelenburg Position on Chronic Subdural Hematoma Recurrence: a Clinical Trial","POTHeR","Inclusion Criteria:\n\n* The study included patients aged 18 years or older who required surgical management of symptomatic CSH confirmed by CT scan and whose informed consent was given by the patient or responsible family member to participate in the study\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding\n* Conditions in which the trendelenburg position might not be safe, such as intracranial hypertension without a drain to allow evacuation of the hematoma, cardiovascular instability (severe heart failure, unstable angina, cardiogenic pulmonary edema), acute respiratory distress syndrome without a secure airway, glaucoma, spinal cord trauma not stabilized with surgery, peripheral vascular disease,\n* History of ipsilateral chronic subdural hematoma drainage, intracranial hypotension syndrome, ventriculoperitoneal shunting\n* Simultaneous participation in any other clinical trial.",{"count":194,"type":21},254,[57],"Objective: Determine the effect of the postoperative trendelenburg position on the recurrence of chronic subdural hematoma (CSH) in patients undergoing surgery.\n\nMaterials and Methods: An open-label, randomized, controlled clinical trial was conducted in three hospitals in Medellín. Patients with CSH were enrolled and assigned to the trendelenburg position (30° leg elevation and 10° head tilt) or a flat bed for 24 hours postoperatively. CSH recurrence was measured at 3 months, along with functional outcome (modified Rankin scale), adverse events, and comfort (Likert scale).",[198,199,200,201,202,203],"Chronic Subdural Hematoma","Trendelenburg","Recurrence","Mortality","Prognosis","Clinical Trials","2025-04-16",{"date":206,"type":36},"2025-04-22",{"date":208,"type":36},"2024-06-01",{"date":210,"type":21},"2027-04-30",{"name":42,"class":43},3,{"id":214,"slug":215,"hasResults":11,"nctId":216,"briefTitle":217,"officialTitle":218,"acronym":4,"eligibilityCriteria":219,"healthyVolunteers":83,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":220,"targetDuration":4,"studyType":22,"phases":222,"briefSummary":224,"conditions":225,"keywords":229,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":241,"lastUpdatePostDateStruct":242,"startDateStruct":244,"completionDateStruct":246,"leadSponsor":248,"locationsCount":44},"100575591","phase-4-analgesic-efficacy-of-intravenous-ketamine-as-a-continuous-infusion-vs-pca-in-the-management-of-acute-postoperative-pain-in-major-orthopedic-surgery-100575591","NCT06774274","Analgesic Efficacy of Intravenous Ketamine as a Continuous Infusion vs PCA in the Management of Acute Postoperative Pain in Major Orthopedic Surgery.","Analgesic Efficacy of Intravenous Ketamine as a Continuous Infusion vs PCA in the Management of Acute Postoperative Pain in Major Orthopedic Surgery: A Randomized Clinical Trial","Inclusion Criteria:\n\n* Patients over 18 years of age\n* Elective major orthopedic surgery.\n* ASA (American Association of Anesthesiology) classification 1, 2 or 3.\n\nExclusion Criteria:\n\n* Patients with a diagnosis of perioperative kidney injury or hepatic failure\n* Patients with active cardiac conditions\n* Patients with any cognitive impairment that disables the patient from operating the PCA pump or impedes the postoperative interview\n* Patients with scheduled ICU admission with invasive ventilatory support\n* Patients with known hypersensitivity to opioid medications\n* Patients with past medical history of severe adverse reactions to opioids or ketamine.\n* Pregnant patients\n* Patients undergoing continuous regional anesthetic techniques including peripheral nerve catheters or continuous epidural catheters\n* Patient refusal to participate in the study",{"count":221,"type":21},120,[223],"PHASE4","The goal of this clinical trial is to determine whether treating pain after surgery with ketamine is more effective when administered intravenously as a continuous infusion or through a patient-controlled analgesia (PCA) pump. This study focuses on adult volunteers following major orthopedic surgery. We have two main questions to address:\n\n* Is a continuous intravenous infusion of ketamine as effective as ketamine administered through a PCA pump for managing pain after major orthopedic surgery.\n* Does a continuous intravenous infusion of ketamine result in lower opioid requirements compared to ketamine delivered through a PCA pump for pain management after major orthopedic surgery?\n\nParticipants will be divided into two groups. One group will receive ketamine via continuous infusion, while the other will receive it through a PCA pump. Both groups will also receive a placebo (a substance that looks like the drug but contains no active ingredients), ensuring that neither group knows whether they are receiving ketamine through the PCA pump (which always contains a painkiller) or as a continuous infusion.\n\nParticipants will be assigned to one of the two groups and will receive their assigned treatment for 48 hours while hospitalized. Researchers will visit participants during their first three days in the hospital to assess their pain levels and monitor for any side effects.",[226,227,228],"Pain, Postoperative","Opioid Use","Major Surgery",[230,231,232,233,234,235,236,237,238,239,240],"postoperative pain","ketamine","patient controlled analgesia","continuous infusion","major surgery","pain","abdominal surgery","thoracic surgery","spine surgery","opioid","major orthopedic surgery","2025-04-08",{"date":243,"type":36},"2025-04-11",{"date":245,"type":36},"2025-03-01",{"date":247,"type":21},"2027-06-15",{"name":42,"class":43},""]